lp-118
Small moleculeexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 23, 2021 (NCT04771572)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Leukemia, Myeloid, Acute · Phase 1/Phase 2
- Leukemia, Myelomonocytic, Chronic · Phase 1
- Leukemia, Prolymphocytic, T-Cell · Phase 1
- Lymphoma, B-Cell · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1
- Multiple Myeloma · Phase 1
- Myelodysplastic Syndromes · Phase 1
- Myeloproliferative Disorders · Phase 1
- Neoplasms · Phase 1
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 1/Phase 2
- Primary Myelofibrosis · Phase 1
Mechanism of action
- Apoptosis regulator Bcl-2INHIBITOR
BCL2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06207123 | Phase 1/Phase 2 (Phase 2) | Sep 13, 2024 | University of Chicago |
| NCT05025358 | Phase 1 | Sep 14, 2021 | Guangzhou Lupeng Pharmaceutical Company LTD., Shantou University |
| NCT04771572 | Phase 1 | Aug 23, 2021 | Newave Pharmaceutical Inc |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Guangzhou Lupeng Pharmaceutical Company LTD. | For profit | 1 | 1 | 1 | 2021 |
| Newave Pharmaceutical Inc | For profit | 1 | 1 | 1 | 2021 |
| Shantou University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Chicago | Academic/Hospital | 1 | 1 | 1 | 2024 |
4 organizations
Page 1 / 1